A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Study Details
Study Description
Brief Summary
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo. The secondary objectives will be to compare the changes in liver fat fraction, other liver function tests, cytokeratin-18 (CK-18) fragment level and adverse event / serious adverse event rates among the interventional and placebo arms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
A randomized, double-blind, placebo controlled study will be conducted in medical centers around Taiwan.
The objective of the study is to investigate the efficacy and safety of SNP-610 for the treatment of NASH, assuming the treatment efficacy of the investigational product is superior to the placebo control.
Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. Eligible subjects will be randomized in a 1:1 ratio to receive study drug or placebo control. Considering a 10% drop-out rate, approximately 80 subjects will be enrolled in order to recruit 70 evaluable subjects, each arm will be at least 35 evaluable subjects to complete the enrollment.
Subjects will be administered the test drugs or placebo oral daily for 3 months or until treatment terminates prematurely. Subjects will return to the study center for clinical evaluation once every 4 weeks throughout the treatment period. Clinical assessment procedures and laboratory tests including ultrasound imaging, hematology with differential, biochemistry, liver function panel, and urinalysis, will be performed at each study visit. The primary endpoint assessment will be the reduction of ALT at completion of Week 12 treatment.
Subjects who finish treatment or discontinue prematurely from the study for any reason after receiving one or more doses of study drug will be assessed for safety for 2 (±1) weeks after the last study drug dose or longer in the case of any significant AE or abnormal biochemical or clinical finding.
Each subject will participate in the study for approximately 14 weeks (including the enrollment/baseline visit, 3 routine monthly visits during treatment period, and 1 follow-up visit after 2 weeks of the end of treatment).
It is assumed the study will include a 6 months enrollment period and a further 4 months to complete the follow-up for all enrolled patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: test drug 2 tabs of SNP-610 |
Drug: SNP-610
Subjects will take 2 tablets once a day orally for 12 weeks
|
| Placebo Comparator: placebo 2 tabs of placebo |
Drug: Placebo Oral Tablet
Subjects will take 2 tablets once a day orally for 12 weeks
|
Outcome Measures
Primary Outcome Measures
- Alanine aminotransferase [12 weeks]
Absolute change from baseline in serum alanine aminotransferase (ALT/GPT)
Secondary Outcome Measures
- MRI liver FF [12 weeks]
Absolute change from baseline in liver fat content
- MRI liver FF [12 weeks]
Relative change from baseline in liver fat content
- Aspartate aminotransferase [12 weeks]
Change in serum level at 12 weeks
- Alkaline phosphatase [12 weeks]
Change in serum level at 12 weeks
- Gamma-glutamyl transpeptidase [12 weeks]
Change in serum level at 12 weeks
- Total bilirubin [12 weeks]
Change in serum level at 12 weeks
- Galactose single point [12 weeks]
Change in serum level at 12 weeks
- CK-18 [12 weeks]
Change in serum level at 12 weeks
Other Outcome Measures
- Insulin resistance [12 weeks]
Change in insulin resistance at Week 12
- Triglycerides [12 weeks]
Changes in serum at Week 12
- Low density lipoprotein [12 weeks]
Changes in serum at Week 12
- Total cholesterol [12 weeks]
Changes in serum at Week 12
- High density lipoprotein [12 weeks]
Changes in serum at Week 12
- Gene expression biomarkers [12 weeks]
Gene expression biomarkers (ACC1, Adfp, AOX, Cat, CCL20, CCR2, Cpt1α, CYP2E1, CYP4A11, CYP7A, Dgat1, Dgat2, FAS, Gapdh, Gpx1, Gpx2, Gpx3, Gpx4, GSS, Hadh, Ho1, HSL, IL-10, IL-1β, IL-6, iNOS, LCAD, NF-κB1, NF-κB2, Pparα, PPARβ/δ, PPARγ, SCD-1, Sod1, Sod2, Sod3, SREBP-1c, TGFβ, TLR4, TNFα, Ucp2, VLCAD, α-SMA, β-actin) related to NASH changes in blood at Week 12
- Rate of patients who experience AEs leading to discontinuation at end of treatment [12 weeks]
- Rate of patients who experience AE/SAE at end of treatment [12 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 20 years
-
Body weight ≥ 54 kg
-
Diagnosis of non-alcoholic steatohepatitis (NASH) as evidenced by imaging or other diagnostic assessments. Subject should have documented liver fat content ≥ 10.0 % as measured by MRI method prior to study drug administration.
-
Alanine aminotransferase (ALT) levels ≥ 2.0x upper limit of normal (ULN) on at least two occasions, seven or more days apart, prior to study drug administration
-
Have adequate organ functions as defined by the following examinations prior to the start of study treatment:
-
Hematology: Hemoglobin ≥ 9 g/dL, a platelet count ≥ 100 x 109/L, and a white blood cell count ≥ 3.0 x 109/L
-
Renal: creatinine clearance ≥ 90 mL/min (by Cockcroft-Gault equation), serum uric acid < 9.0 mg/dL
-
Able to provide written informed consent, and understand and comply with the requirements of the study
Exclusion Criteria:
-
Decompensated or severe liver disease as evidenced by one or more of the following:
-
Confirmed cirrhosis or suspicion of cirrhosis
-
Liver transplant
-
Liver malignancy
-
Ascites
-
Bilirubin >2 x ULN, or ALT or AST > 10 x ULN
-
Acute or chronic hepatitis A, B, C, HIV, or other liver diseases affecting liver function.
Patients with cysts, hemangiomas, or similar abnormalities, are accepted.
-
History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years
-
Subjects who are unable to undergo an MRI scan.
-
Subjects have electronically, magnetically and mechanically activated implanted devices, including but not limited to automatic cardioverter defibrillators, cardiac pacemakers, insulin pumps, metallic splinters in the eye, ferromagnetic haemostatic clips in central nervous systems or vascular vessels.
-
Significant systemic or major illness other than liver disease, including auto-immune disease, coronary artery disease, cerebrovascular disease, malignant neoplasms, pulmonary disease, renal insufficiency, serious psychiatric disease, and/or other serious disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study
-
Documented history of serious allergic reaction to SNP-610 or any structurally related compounds
-
Diabetic patients who have not maintained a stable dose of oral medication for hyperglycemia or have had more than 10 percent change in their insulin dose over the past two months
-
Regular use of agents that are potent against hepatitis or affecting lipid metabolisms, including but not limited to HMGCoA reductase inhibitors (statins), fibrates, silymarin, N-acetylcysteine, or anti-TNF therapies.
Note: refer to Section 6.5 Prohibited agents for details.
-
Pregnant or lactating
-
Female of child-bearing potential who are not committed to take reliable contraception during the participation of the study and at least 4 weeks after the end of the study treatment
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sinew Pharma Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SNP-610-201